Caramazza et al evaluated the impact of cytogenetics on survival in patients with myelofibrosis. The authors are from the University of Palermo and the Mayo Clinic.
Unfavorable cytogenetics include:
(1) complex phenotype (3 or more abnormalities)
(2) presence of one the following alone or in combination with another:
(2a) +8 (trisomy 8)
(2b) -7/q-
(2c) i(17q)
(2d) -5/5q-
(2e) inv(3)
(2f) 11q23 rearrangement
(2g) 12p-
If the patient does not have an unfavorable karyotype then the karyotype is considered favorable.
A platelet count < 100,000 per µL was associated with disease progression (with leukemic transformation).
To read more or access our algorithms and calculators, please log in or register.
